09.19.2023
Prevent & Delay
$1,508,250.00
36 months
Engineering antigen-specific regulatory T cells for use in type 1 diabetes (Phase 3)
Funds will support studies to develop an engineered targeted Treg cell therapy to treat type 1 diabetes.